Oncobiologics (OTLK) Competitors $2.07 +0.05 (+2.48%) Closing price 04:00 PM EasternExtended Trading$2.09 +0.02 (+0.97%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. ACB, IMMP, CRDF, FENC, SLRN, MNPR, PRQR, NBTX, TVGN, and CGCShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Aurora Cannabis (ACB), Prima BioMed (IMMP), Cardiff Oncology (CRDF), Adherex Technologies (FENC), Acelyrin (SLRN), Monopar Therapeutics (MNPR), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Semper Paratus Acquisition (TVGN), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Aurora Cannabis Prima BioMed Cardiff Oncology Adherex Technologies Acelyrin Monopar Therapeutics ProQR Therapeutics Nanobiotix Semper Paratus Acquisition Canopy Growth Oncobiologics (NASDAQ:OTLK) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Does the media refer more to OTLK or ACB? In the previous week, Oncobiologics and Oncobiologics both had 3 articles in the media. Oncobiologics' average media sentiment score of 1.08 beat Aurora Cannabis' score of 0.72 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer OTLK or ACB? Oncobiologics currently has a consensus target price of $9.60, indicating a potential upside of 363.77%. Given Oncobiologics' higher possible upside, equities analysts plainly believe Oncobiologics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Which has more risk & volatility, OTLK or ACB? Oncobiologics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Is OTLK or ACB more profitable? Aurora Cannabis has a net margin of 1.32% compared to Oncobiologics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Oncobiologics' return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -271.12% Aurora Cannabis 1.32%0.13%0.10% Which has higher valuation and earnings, OTLK or ACB? Aurora Cannabis has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.91-2.27Aurora Cannabis$246.72M1.02$1.63M$0.1140.82 Do insiders and institutionals hold more shares of OTLK or ACB? 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 4.8% of Oncobiologics shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryAurora Cannabis beats Oncobiologics on 11 of the 15 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.81M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-2.277.5819.7619.92Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book-0.677.638.045.49Net Income-$75.37M-$55.05M$3.18B$250.27M7 Day Performance14.36%8.54%3.72%4.78%1 Month Performance15.64%5.38%3.72%7.20%1 Year Performance-75.30%2.35%29.92%17.27% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.371 of 5 stars$2.07+2.5%$9.60+363.8%-73.5%$67.81MN/A-2.2720Positive NewsACBAurora Cannabis0.3716 of 5 stars$4.43-2.4%N/A-17.6%$249.01M$246.72M40.271,130IMMPPrima BioMed1.5932 of 5 stars$1.68-2.3%$7.00+316.7%-18.0%$245.35M$5.14M0.002,021Positive NewsCRDFCardiff Oncology1.4529 of 5 stars$3.65-0.3%$9.88+170.5%+88.2%$242.83M$680K-3.9720Analyst ForecastFENCAdherex Technologies2.2528 of 5 stars$8.47-3.8%$13.00+53.5%+50.7%$233.77M$47.54M-16.6110SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135MNPRMonopar Therapeutics2.0394 of 5 stars$37.20+2.6%$60.00+61.3%+986.9%$227.66MN/A-10.6910Analyst RevisionPRQRProQR Therapeutics2.6293 of 5 stars$2.14-1.8%$8.00+273.8%+38.0%$225.15M$20.46M-6.11180Analyst ForecastNBTXNanobiotix2.8029 of 5 stars$4.75-2.5%$8.00+68.6%-0.8%$223.68M$39.18M0.00100Positive NewsTVGNSemper Paratus Acquisition4.0366 of 5 stars$1.20-3.2%$10.00+733.3%+76.8%$220.67MN/A0.003CGCCanopy Growth0.4216 of 5 stars$1.20-6.3%$2.00+66.7%-81.2%$220.64M$225.65M-0.303,150 Related Companies and Tools Related Companies Aurora Cannabis Competitors Prima BioMed Competitors Cardiff Oncology Competitors Adherex Technologies Competitors Acelyrin Competitors Monopar Therapeutics Competitors ProQR Therapeutics Competitors Nanobiotix Competitors Semper Paratus Acquisition Competitors Canopy Growth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
